StreetAlpha
13F holdings · Q3 2026

Kalehua Capital Management

Dallas, TX · files as Kalehua Capital Management LLC
Know the moment Kalehua Capital Management filesYou follow Kalehua Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 2106181

Kalehua Capital Management reported 22 stocks worth $132M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are MANE (13.3%), BOXX (13.3%) and KRSA (10.7%). Compared with Q2 2026, the fund opened new positions in KRSA, BETRF and OBX, added to KRRO, trimmed MANE, BOXX and XFOR and sold out of CMPS, SION and PHVS.

Latest filing: what Kalehua Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
8 new1 added13 trimmed12 sold outBought about $36.7M · sold about $197M
New 8
See all 8 →
Added 1
Trimmed 13
See all 13 →
Sold out 12
See all 12 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$132M−57.8% vs last quarter
Stocks held228 new · 12 sold out
Top 5 weight52.8%fairly concentrated
Turnover177%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
MANE
Veradermics Inc
$17.7M13.3%146K−146K (−50%)3 of 4
2
BOXX
EA Series Trust
$17.6M13.3%148K−78K (−34%)4 of 4
3
KRSA
Korsana Biosciences Inc
$14.2M10.7%443KNew position1 of 4
4
XFOR
X4 Pharmaceuticals Inc
$10.8M8.2%3.7M−3.7M (−50%)4 of 4
5
ACRS
Aclaris Therapeutics Inc
$9.6M7.3%1.8M−1.8M (−50%)3 of 4
6
SRZN
Surrozen Inc
$9.2M7.0%286K−484K (−63%)4 of 4
7
IKT
Inhibikase Therapeutics Inc
$7.9M5.9%3.8M−3.8M (−50%)4 of 4
8
SEPN
Septerna Inc
$7.6M5.8%195K−195K (−50%)4 of 4
9
BETRF
Betterlife Pharma Inc
$6.7M5.0%27.7MNew position1 of 4
10
OBX
Obsidian Therapeutics Inc
$5.7M4.3%417KNew position1 of 4
🔒 12 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
CMPS
Compass Pathways PLC
$23.2M1.6M
SION
Sionna Therapeutics Inc
$17.3M394K
PHVS
Pharvaris N V
$13.7M398K
KPTI
Karyopharm Therapeutics Inc
$13.4M1.4M
CYCLERION THERAPEUTICS INC
$11.2M3.3M

🔒 Free account: see all 12.

Reported value

last 4 quarters
$101MQ4 '25
$260MQ1 '26
$313MQ2 '26
$132MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Kalehua Capital Management 13F FAQ

What does Kalehua Capital Management own?

Kalehua Capital Management reported 22 stocks worth $132M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are MANE (13.3%), BOXX (13.3%) and KRSA (10.7%). The table above lists every position in the filing (the top 10 without an account).

What did Kalehua Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 8 new positions, 1 added to, 13 trimmed and 12 sold out. New positions include KRSA, BETRF and OBX. It sold all of CMPS, SION and PHVS.

When will Kalehua Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Kalehua Capital Management's portfolio worth?

The Q3 2026 filing reports $132M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.